Melbourne Melanoma Project committed to improving the diagnosis and early detection of melanoma.

Study Shows Efficacy of Neoadjuvant Combo Therapy in Melanoma, Cautions Toxicity

Source: Specialty Pharmacy Times, November 2018 A neoadjuvant therapeutic approach demonstrated a clinical benefit for patients with high-risk melanoma, but toxicity concerns suggest the need for further optimization to reduce adverse effects, according to a new study. In the phase 2 study, which was published in Nature Medicine, researchers at The University of Texas MD Anderson […]

Evaluating the Role of the Gut Microbiome to Bolster Immunotherapy Response in Melanoma

Source: Targeted Oncology, November 2018 A new area of research in the treatment landscape of melanoma focuses on manipulating the gut microbiome to improve immunotherapy responses, particularly with anti–PD-1 and anti–CTLA-4 antibodies. Based on data seen in several mouse studies in Chicago and France, it is suggested that altering the microbiome may be necessary to […]

Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC

Source: Cancer Therapy Advisor, November 2018 More patients with melanoma who were treated with either nivolumab or pembrolizumab developed immune-related adverse events (irAEs) compared with patients with non-small cell lung cancer (NSCLC) treated with these same checkpoint inhibitors, suggesting differences in these events across groups. However, more studies will be needed to determine whether the association between […]

Combining genetic and sun exposure data improves skin cancer risk estimates

Source: Ecancer News, November 2018 By combining data on individuals’ lifetime sun exposure and their genetics, researchers can generate improved predictions of their risk of skin cancer, according to findings presented at the American Society of Human Genetics (ASHG) 2018 Annual Meeting in San Diego, Calif. Pierre Fontanillas, PhD, and colleagues at 23andMe, Inc., collected genetic and […]